Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00376935 |
|
Recruitment Status :
Completed
First Posted : September 15, 2006
Results First Posted : January 30, 2012
Last Update Posted : February 15, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Infections | Drug: Palifermin Drug: Palifermin placebo | Phase 2 |
Antiretroviral therapy (ART) has dramatically improved the clinical outcome for HIV infected adults; however, some people on potent ART experience poor recovery of CD4 counts despite maximum suppression of viral load. Such uncontrolled HIV infection is associated with the reduced ability by the human body to create new T cells (or thymopoiesis). HIV infected adults experiencing reduced thymopoiesis are at increased risk of clinical disease progression.
The thymus is the primary site for CD4 cell development; research suggests that keratinocyte growth factor (KGF) may enhance thymus activity in individuals who exhibit reduced thymopoiesis. Palifermin is a modified version of the naturally occurring KGF that is approved to treat people with hematologic malignancies. The purpose of this study is to evaluate the safety and efficacy of palifermin in increasing CD4 counts, through enhanced thymopoiesis, in treatment-experienced HIV infected adults with suppressed viral loads but low CD4 counts.
This study will last 24 weeks. Participants will be randomly assigned to one of four arms:
- Arm A participants will receive placebo
- Arm B participants will receive palifermin 20 mcg/kg
- Arm C participants will receive palifermin 40 mcg/kg
- Arm D participants will receive palifermin 60 mcg/kg
Participants will receive intravenous doses of their assigned intervention on Days 1, 2, and 3. All participants must remain on their current ART regimen for the duration of the study. ART will not be provided by the study. There will be six study visits, and they will occur at Weeks 1, 2, 4, 8, 12, and 24. All visits will include a targeted physical exam and blood and urine collection.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 99 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Care Provider) |
| Primary Purpose: | Treatment |
| Official Title: | A Double Blind Phase II Study of Multiple Doses of Palifermin (rHuKGF) for the Treatment of Inadequate CD4+ Lymphocyte Recovery in Subjects on Potent Antiretroviral Therapy With Plasma HIV-1 RNA Levels of 200 Copies Per Milliliter or Less |
| Study Start Date : | December 2006 |
| Actual Primary Completion Date : | July 2008 |
| Actual Study Completion Date : | September 2008 |
| Arm | Intervention/treatment |
|---|---|
|
Placebo Comparator: 1
Participants will receive palifermin placebo injection on Days 1, 2, and 3
|
Drug: Palifermin placebo
Keratinocyte growth factor placebo administered via injection
Other Name: rHuKGF placebo |
|
Experimental: 2
Participants will receive palifermin 20 mcg/kg injection on Days 1, 2, and 3
|
Drug: Palifermin
Keratinocyte growth factor administered via injection
Other Name: rHuKGF |
|
Experimental: 3
Participants will receive palifermin 40 mcg/kg injection on Days 1, 2, and 3
|
Drug: Palifermin
Keratinocyte growth factor administered via injection
Other Name: rHuKGF |
|
Experimental: 4
Participants will receive palifermin 60 mcg/kg injection on Days 1, 2, and 3
|
Drug: Palifermin
Keratinocyte growth factor administered via injection
Other Name: rHuKGF |
- Change in Absolute CD4+ Lymphocyte Counts From Baseline (Average of Pre-entry and Entry Values) [ Time Frame: Pre-entry, entry, study week 12 ]Median and inter-quartile range of the change in absolute CD4 count from baseline to study week 12 were calculated for each treatment arm. Baseline CD4+ count was defined as the average of pre-entry and entry CD4 count. If one evaluation was missing, the other one was used. If a subject missed a week 12 CD4 count evaluation, then the CD4 count evaluation obtained after starting study treatment and closest in time to week 12 (using the earlier evaluation if necessary to break a tie) was used in place of the missing week 12 evaluation.
- Qualitative Hepatitis C Virus RNA [ Time Frame: At study entry ]
- Grade 3 or 4 Toxicity for Signs and Symptoms From Randomization to Week 24 [ Time Frame: From randomization to week 24 ]Number of subjects had a grade 3 or 4 toxicity for signs and symptoms. The toxicity grade scale has the following meaning: 1=mild, 2=moderate, 3=severe, 4=life-threatening.
- Change in Naive CD4+ Cell Counts From Randomization [ Time Frame: randomization, day 2, study weeks 1, 2, 4, 8, 12 and 24 ]
- Change in CT Thymic Index From Randomization [ Time Frame: randomization, study week 12 ]CT thymic index was evaluated at randomization and study week 12, ranging from 0 to 5 whereby 0 means lack of thymic tissue and an organ entirely replaced by fat, 1 means barely recognizable thymic tissue, 2 means minimal soft tissue, 3 means obvious thymic tissue, 4 means moderate thymic tissue, 5 means thymic mass of possible concern for thymoma. Change in CT thymic index from randomization to study week 12 was calculated for participants with both evaluations. The number of participants in each change group was reported by treatment arm.
- Change in Absolute CD4+ Lymphocyte Counts From Randomization to Day 2, Weeks 1, 2, 4, 8, 12, 24. [ Time Frame: randomization, day 2, study weeks 1, 2, 4, 8, 12 and 24 ]
- Grade 3 or 4 Lab Toxicities From Randomization to Week 24 [ Time Frame: From randomization to study week 24 ]Number of subjects had a grade 3 or 4 toxicity for laboratory abnormalities. The toxicity grade scale has the following meaning: 1=mild, 2=moderate, 3=severe, 4=life-threatening.
- Number of Death From Randomization to Week 24 [ Time Frame: From randomization to week 24 ]Number of subjects died.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV infected
- Receiving potent ART, defined as a combination of three or more antiretroviral drugs for at least 6 months prior to study entry
- CD4 count of 200 cells/mm3 or less within 30 days prior to study entry
- Documented CD4 count obtained at study screening
- Documented current, persistent viral load less than or equal to 200 copies/ml for at least 6 months prior to study entry
- Willing to use acceptable forms of contraception for the duration of the study
Exclusion Criteria:
- Active pancreatitis
- Androgens, Immunomodulators (e.g., growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons), or investigational ART within 30 days prior to study entry
- Systemic cancer chemotherapy within 30 days prior to study entry, or history of radiation therapy to the neck and chest regions at any time.
- Allergy or sensitivity to any component of palifermin
- Prior treatment with palifermin or other keratinocyte growth factors
- Current drug or alcohol use that, in the opinion of the investigator, may interfere with study participation
- Serious illness or recent surgery that requires systemic treatment or hospitalization. Participants who have completed therapy or are clinically stable on therapy for at least 30 days prior to study entry are not excluded.
- Active cancer
- HIV-1 RNA levels >200 copies/mL within 6 months prior to study entry
- Pregnant or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376935
Show 22 study locations
| Study Chair: | Jeffrey M. Jacobson, MD | Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine |
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00376935 |
| Other Study ID Numbers: |
A5212 10147 ( Registry Identifier: DAIDS ES ) ACTG A5212 |
| First Posted: | September 15, 2006 Key Record Dates |
| Results First Posted: | January 30, 2012 |
| Last Update Posted: | February 15, 2019 |
| Last Verified: | January 2019 |
|
Treatment Experienced |
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |